← Back to Search

MedReviewRx for Overmedication

N/A
Waitlist Available
Led By Emily McDonald, MD
Research Sponsored by Centre for Innovation and Research in Aging, Canada
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Summary

This trial tests MedReviewRx, an app that helps doctors and pharmacists review and simplify medications for older adults in New Brunswick nursing homes. The goal is to reduce unnecessary or harmful medications, making treatment safer and potentially lowering costs. The app analyzes medications and health conditions, providing reports to guide safer prescribing.

Eligible Conditions
  • Overmedication
  • Deprescribing
  • Adverse Drug Reactions

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Impact of MedReviewRx on the prevalence of potentially inappropriate medications (PIMs) in New Brunswick nursing homes (NBNHs).
Secondary study objectives
Change in functional status based on interRAI activities of daily living (ADL) scores.
Number of changes from baseline in composite safety data
Number of deaths
+10 more
Other study objectives
Cost savings
Patient and family attitudes about deprescribing

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: MedReviewRxExperimental Treatment1 Intervention
During the intervention phase, MedReviewRx will be made available to nursing homes with the understanding that it will be used to facilitate medication reviews and prescription check-ups. MedReviewRx provides clinicians with access to individualized and prioritized deprescribing information from MedSafer which: a) identifies potentially inappropriate medications (PIMs), b) explains why the medication is potentially inappropriate and c) provides instructions on how to safely stop/taper the medication.
Group II: No MedReviewRxActive Control1 Intervention
During the control phase, MedReviewRx will not be accessible to health care professionals at the nursing homes. This serves to obtain baseline deprescribing levels for each nursing home.

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER
465 Previous Clinical Trials
165,283 Total Patients Enrolled
Horizon Health NetworkOTHER
29 Previous Clinical Trials
15,805 Total Patients Enrolled
Missing Link TechnologiesUNKNOWN
~240 spots leftby Oct 2025